ATE362470T1 - 3,4-dihydroisoquinolinderivat-verbindungen und diese verbindungen als aktiven inhaltsstoff enthaltende arzneimittel - Google Patents

3,4-dihydroisoquinolinderivat-verbindungen und diese verbindungen als aktiven inhaltsstoff enthaltende arzneimittel

Info

Publication number: ATE362470T1
Authority: AT; Austria
Prior art keywords: compounds; active ingredients; products containing; medicinal products; dihydroisoquinoline derivative
Prior art date: 2000-08-01

Application number

AT01953336T

Other languages

English (en)

Inventor

Mikio Ogawa

Y Takaoka

Akira Ohhata

Original Assignee

Ono Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-01

Filing date

2001-07-30

Publication date

2007-06-15

2001-07-30 Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co

2007-06-15 Application granted granted Critical

2007-06-15 Publication of ATE362470T1 publication Critical patent/ATE362470T1/de

Links

-1 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS Chemical class 0.000 title abstract 2
239000004480 active ingredient Substances 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title abstract 2
229940126601 medicinal product Drugs 0.000 title 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
102000009135 CB2 Cannabinoid Receptor Human genes 0.000 abstract 1
108010073376 CB2 Cannabinoid Receptor Proteins 0.000 abstract 1
206010012438 Dermatitis atopic Diseases 0.000 abstract 1
206010020751 Hypersensitivity Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
208000004550 Postoperative Pain Diseases 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
230000007815 allergy Effects 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
201000008937 atopic dermatitis Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
239000008177 pharmaceutical agent Substances 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

AT01953336T 2000-08-01 2001-07-30 3,4-dihydroisoquinolinderivat-verbindungen und diese verbindungen als aktiven inhaltsstoff enthaltende arzneimittel ATE362470T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2000232911		2000-08-01

Publications (1)

Publication Number	Publication Date
ATE362470T1 true ATE362470T1 (de)	2007-06-15

Family

ID=18725515

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01953336T ATE362470T1 (de)	2000-08-01	2001-07-30	3,4-dihydroisoquinolinderivat-verbindungen und diese verbindungen als aktiven inhaltsstoff enthaltende arzneimittel

Country Status (20)

Country	Link
US (1)	US6956033B2 (de)
EP (1)	EP1306373B1 (de)
JP (1)	JP4982937B2 (de)
KR (1)	KR20030017660A (de)
CN (1)	CN1466577A (de)
AT (1)	ATE362470T1 (de)
AU (1)	AU2001275798A1 (de)
BR (1)	BR0112883A (de)
CA (1)	CA2417156A1 (de)
CZ (1)	CZ2003284A3 (de)
DE (1)	DE60128476D1 (de)
HU (1)	HUP0303070A2 (de)
IL (1)	IL154082A0 (de)
MX (1)	MXPA03000952A (de)
NO (1)	NO20030490L (de)
NZ (1)	NZ523839A (de)
PL (1)	PL362916A1 (de)
RU (1)	RU2272030C2 (de)
WO (1)	WO2002010135A1 (de)
ZA (1)	ZA200300619B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003061699A1 (en) *	2001-12-27	2003-07-31	Japan Tobacco, Inc.	Remedies for allergic diseases
TW200302726A (en) *	2002-01-31	2003-08-16	Ono Pharmaceutical Co	Nitrogen-containing bicyclic compound and medicament containing same as active ingredient
WO2003075917A1 (en)	2002-03-08	2003-09-18	Signal Pharmaceuticals, Inc.	Combination therapy for treating, preventing or managing proliferative disorders and cancers
EP1661572A1 (de) *	2003-08-18	2006-05-31	Shionogi & Co., Ltd.	Neue verwendung von cannabinoid-rezeptor-agonisten
TW200533657A (en) *	2004-02-17	2005-10-16	Esteve Labor Dr	Substituted pyrazoline compounds, their preparation and use as medicaments
AR051596A1 (es) *	2004-10-26	2007-01-24	Irm Llc	Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
TWI360539B (en) *	2004-10-28	2012-03-21	Shionogi & Co	3-carbamoyl-2-pyridone derivatives
AU2005316739A1 (en) *	2004-12-13	2006-06-22	Galileo Pharmaceuticals, Inc.	Spiro derivatives as lipoxygenase inhibitors
US20060160850A1 (en)	2005-01-18	2006-07-20	Chongqing Sun	Bicyclic heterocycles as cannabinoid receptor modulators
EP1743892A1 (de) *	2005-07-15	2007-01-17	Laboratorios del Dr. Esteve S.A.	Substituierte Pyrazolin Verbindungen, deren Herstellung und Verwendung als Medikament
US7897589B2 (en) *	2005-07-15	2011-03-01	Laboratorios Del Dr. Esteve, S.A.	Substituted pyrazoline compounds, their preparation and use as medicaments
EP1757587A1 (de) *	2005-07-15	2007-02-28	Laboratorios Del Dr. Esteve, S.A.	Substituierte Pyrazolinderivate, ihre Herstellung und Verwendung als Arzneimittel
EP1743890A1 (de) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	4,5-Dihydro-1H-Pyrazol-Derivative, Verfahren zur Herstellung und ihre Verwendung als Medikamente.
BRPI0706365A2 (pt) *	2006-01-06	2011-03-22	Sepracor Inc	Cicloalquilaminas como inibidores da recaptação de monoamina
KR101373087B1 (ko) *	2006-10-30	2014-03-11	산메디카루 가부시키가이샤	치과용 셀프 에칭 프라이머 조성물
RU2326114C1 (ru) *	2006-11-20	2008-06-10	Государственное учреждение Институт технической химии Уральского отделения Российской академии наук (ИТХ УрО РАН)	Способ получения 1-замещенных 3,3,4,4-тетраметил-3,4-дигидроизохинолинов
WO2008088744A1 (en) *	2007-01-17	2008-07-24	Merck & Co., Inc.	Decahydroquinoline analogs as cb2 receptor modulators
US20100130603A1 (en)	2007-03-09	2010-05-27	Kyoto University	Medicament for prophylactic and therapeutic treatment of dermatosis resulting from excessively advanced keratinization
RU2374232C1 (ru) *	2008-07-04	2009-11-27	Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет"	(2z,5z)-1-арил-3-гидрокси-5-(3,3-диметил-3,4-дигидроизохинолин-1(2н)-илиден)-пент-2-ен-1,4-дионы и способ их получения
EP2151234A1 (de) *	2008-07-28	2010-02-10	Laboratorios Del. Dr. Esteve, S.A.	Pharmazeutische Formulierung mit einer CB1-Rezeptorverbindung in einer festen Lösung und/oder festen Dispersion
RU2374231C1 (ru) *	2008-11-19	2009-11-27	Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет"	(1z,3z)-4-арил-4-гидрокси-1-(3,3-диалкил-3,4-дигидроизохинолин-1(2h)-илиден)-бут-3-ен-4-оны и способ их получения
WO2010080503A1 (en) *	2008-12-19	2010-07-15	Genentech, Inc.	Heterocyclic compounds and methods of use
WO2010147133A1 (ja)	2009-06-17	2010-12-23	小野薬品工業株式会社	新規なイミダゾピリジン化合物
US20120277296A1 (en)	2009-07-23	2012-11-01	Sophie Lotersztajn	Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease
ES2642586T3 (es)	2009-07-27	2017-11-16	Gilead Sciences, Inc.	Compuestos heterocíclicos condensados como moduladores de canales iónicos
RU2417221C1 (ru) *	2009-11-02	2011-04-27	Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет"	(1z,3z)-4-арил-4-гидрокси-1-(3,3-диалкил-3,4-дигидроизохинолин-1(2н)-илиден)-бут-3-ен-4-оны и способ их получения
EP2588197B1 (de)	2010-07-02	2014-11-05	Gilead Sciences, Inc.	Kondensierte heterozyklische verbindungen als ionenkanalmodulatoren
WO2012037349A2 (en) *	2010-09-17	2012-03-22	Glaxosmithkline Llc	Compounds
WO2012037351A1 (en) *	2010-09-17	2012-03-22	Glaxosmithkline Llc	Compounds
KR20140033377A (ko)	2011-05-10	2014-03-18	길리애드 사이언시즈, 인코포레이티드	나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
UY34171A (es)	2011-07-01	2013-01-31	Gilead Sciences Inc	Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (de)	2011-07-01	2018-04-28
US8889675B2 (en)	2011-10-14	2014-11-18	Abbvie Inc.	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8940737B2 (en)	2011-10-14	2015-01-27	Abbvie Inc.	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP6662901B2 (ja) *	2015-03-27	2020-03-11	シンジェンタパーティシペーションズアーゲー	殺微生物性二環式複素環式誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1470084A1 (de) *	1964-08-19	1969-05-29	Merck Ag E	Verfahren zur Herstellung von substituierten Piperidin-derivaten
HU196758B (en) *	1986-05-21	1989-01-30	Gyogyszerkutato Intezet	Process for production of 3-hidroxi-methil-quinolines and medical compositions containing them
DE3718570A1 (de) *	1987-06-03	1988-12-15	Boehringer Ingelheim Kg	Benzo- und thieno-3,4-dihydro-1- pyridinylessigsaeurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5532237A (en) *	1995-02-15	1996-07-02	Merck Frosst Canada, Inc.	Indole derivatives with affinity for the cannabinoid receptor
WO1997029079A1 (en)	1996-02-06	1997-08-14	Japan Tobacco Inc.	Novel compounds and pharmaceutical use thereof
US5948777A (en)	1997-03-18	1999-09-07	Smithkline Beecham Corporation	Cannabinoid receptor agonists
FR2783246B1 (fr)	1998-09-11	2000-11-17	Aventis Pharma Sa	Derives d'azetidine, leur preparation et les medicaments les contenant

2001
- 2001-07-30 CZ CZ2003284A patent/CZ2003284A3/cs unknown
- 2001-07-30 BR BR0112883-3A patent/BR0112883A/pt not_active IP Right Cessation
- 2001-07-30 EP EP01953336A patent/EP1306373B1/de not_active Expired - Lifetime
- 2001-07-30 US US10/333,591 patent/US6956033B2/en not_active Expired - Fee Related
- 2001-07-30 CA CA002417156A patent/CA2417156A1/en not_active Abandoned
- 2001-07-30 AT AT01953336T patent/ATE362470T1/de not_active IP Right Cessation
- 2001-07-30 AU AU2001275798A patent/AU2001275798A1/en not_active Abandoned
- 2001-07-30 IL IL15408201A patent/IL154082A0/xx unknown
- 2001-07-30 PL PL01362916A patent/PL362916A1/xx unknown
- 2001-07-30 MX MXPA03000952A patent/MXPA03000952A/es unknown
- 2001-07-30 CN CNA01816496XA patent/CN1466577A/zh active Pending
- 2001-07-30 HU HU0303070A patent/HUP0303070A2/hu unknown
- 2001-07-30 RU RU2003102888/04A patent/RU2272030C2/ru not_active IP Right Cessation
- 2001-07-30 NZ NZ523839A patent/NZ523839A/en unknown
- 2001-07-30 KR KR10-2003-7001424A patent/KR20030017660A/ko not_active Withdrawn
- 2001-07-30 DE DE60128476T patent/DE60128476D1/de not_active Expired - Lifetime
- 2001-07-30 WO PCT/JP2001/006541 patent/WO2002010135A1/ja not_active Ceased
- 2001-07-30 JP JP2002516267A patent/JP4982937B2/ja not_active Expired - Fee Related
2003
- 2003-01-22 ZA ZA200300619A patent/ZA200300619B/xx unknown
- 2003-01-30 NO NO20030490A patent/NO20030490L/no unknown

Also Published As

Publication number	Publication date
CZ2003284A3 (cs)	2003-09-17
JP4982937B2 (ja)	2012-07-25
EP1306373A1 (de)	2003-05-02
WO2002010135A1 (en)	2002-02-07
NO20030490L (no)	2003-03-27
EP1306373A4 (de)	2004-09-01
IL154082A0 (en)	2003-07-31
US20040077643A1 (en)	2004-04-22
MXPA03000952A (es)	2003-09-05
CN1466577A (zh)	2004-01-07
HUP0303070A2 (hu)	2003-12-29
KR20030017660A (ko)	2003-03-03
CA2417156A1 (en)	2003-01-23
RU2272030C2 (ru)	2006-03-20
NZ523839A (en)	2005-07-29
DE60128476D1 (de)	2007-06-28
EP1306373B1 (de)	2007-05-16
ZA200300619B (en)	2004-05-20
AU2001275798A1 (en)	2002-02-13
US6956033B2 (en)	2005-10-18
BR0112883A (pt)	2003-06-24
PL362916A1 (en)	2004-11-02
NO20030490D0 (no)	2003-01-30

Legal Events

Date	Code	Title	Description
2007-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE362470T1 (de)	2007-06-15	3,4-dihydroisoquinolinderivat-verbindungen und diese verbindungen als aktiven inhaltsstoff enthaltende arzneimittel
ATE283854T1 (de)	2004-12-15	Triazaspiro(5.5)undecan-derivate und drogen, die dasselbe als aktiven inhaltsstoff enthalten
ATE328884T1 (de)	2006-06-15	Triazaspiro (5.5) undecanderivate und arzneimittel, die diese derivate als wirkstoff enthalten
GEP20033025B (en)	2003-07-25	4,4-Biarylpiperidine Derivatives with Opioid Receptor Activity
TNSN04113A1 (en)	2006-06-01	3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
WO2003024955A3 (en)	2003-08-14	Small molecule inhibitors of caspases
NO20053645L (no)	2002-10-22	(4R)- og (4S)-diastereoisomerer av (2S)-2-[ 2-oksy-4-propylpyrrolidinyl]butanamid og farmasoytisk preparat inneholdende disse
BR0212829A (pt)	2004-08-03	Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados
HUP9801331A2 (hu)	1999-05-28	Triciklusos amid- és karbamidszármazékok a G-protein funkció gátlására és daganatos betegségek kezelésére, új triciklusos amid- és karbamidszármazékok, alkalmazásuk, a vegyületeket hatóanyagként tartalmazó gyógyszerkészítmények
GEP20012439B (en)	2001-05-25	Aniline Derivatives Having Nitrogen Monoxide Synthase Inhibitory Activity and Pharmaceutical Compositions Containing the Same
GR3020050T3 (en)	1996-08-31	Leukotriene B4 antagonist
EP1509220A4 (de)	2009-04-01	Pharmazeutische zusammensetzung zur behandlung von seborrhoe mit 4-hydroxy-5-methoxy-4-2-methyl-3(3-methyl-2-butenyl)-2-oxiranyl -1-oxaspiro 2,5 octan-6-on
DE69500673D1 (de)	1997-10-16	Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
NO323466B1 (no)	2007-05-21	Nye kinolinyl-piperidin-4-yliden-metyl-benzamidderivater, fremgangsmate til fremstilling derav, anvendelse derav i medikamenter til behandling av smerte, samt farmasoytisk sammensetning som innbefatter slike derivater
EP1254898A4 (de)	2003-03-12	Benzokondensierte heterocyclische derivate sowie diese als wirkstoffe enthaltende medikamente
ATE437636T1 (de)	2009-08-15	Pharmazeutische zusammensetzungen die ein dibenzocyclooctanlignanderivat enthalten zur vorbeugung und behandlung neurodegenerativer erkrankungen
PT889044E (pt)	2005-01-31	Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
ATE265459T1 (de)	2004-05-15	Triazolpurin-derivate, medikamentzusammensetzungen, die diese enthalten und mittel, die affinität zum adenosin a3 rezeptor zeigen
ATE402178T1 (de)	2008-08-15	Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten
TH63164A (th)	2004-07-30	โพรดรักของอนุพันธ์ 3-(ไพรโรล-2-อิลเมธิลิดีน)-2-อิลโดลิโนน
TH65773A (th)	2004-12-23	อนุพันธ์อินโดลชนิดใหม่ใช้เป็นสารยับยั้ง Xa แฟกเตอร์
TH42378A (th)	2001-01-10	'' โพรีดีนส์ถูกแทนที่ของ 2-อะมิโน-6- (2-ถูกแทนที่-4-พีนอกซี)
TH33733A (th)	1999-07-09	ไตรเอโซโลฟิวรีนส์ชนิดใหม่ ขบวนการสำหรับการเตรียมสารเหล่านี้และการใช้ประโยชน์ในการเป็นผลิตภัณฑ์ยาของสารเหล่านี้
TH39271A (th)	2000-07-10	อนุพันธ์สไปโร-ไพเพอริดีน และการใช้งานของสิ่งเหล่านั้นเป็นสารอายุรเวช
TH58172A3 (th)	2003-09-10	สารประกอบทางเภสัชกรรม